{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["MD simulation", "antiproliferative", "apoptosis", "cell cycle analysis", "docking study", "pharmacophore search", "pyrrolizine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34209011", "DateCompleted": {"Year": "2021", "Month": "07", "Day": "14"}, "DateRevised": {"Year": "2021", "Month": "07", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "06", "Day": "30"}], "Language": ["eng"], "ELocationID": ["4002", "10.3390/molecules26134002"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "13", "PubDate": {"Year": "2021", "Month": "Jun", "Day": "30"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases.", "Abstract": {"AbstractText": ["In the current study, a simple in silico approach using free software was used with the experimental studies to optimize the antiproliferative activity and predict the potential mechanism of action of pyrrolizine-based Schiff bases. A compound library of 288 Schiff bases was designed based on compound <b>10,</b> and a pharmacophore search was performed. Structural analysis of the top scoring hits and a docking study were used to select the best derivatives for the synthesis. Chemical synthesis and structural elucidation of compounds <b>16a-h</b> were discussed. The antiproliferative activity of <b>16a</b>-<b>h</b> was evaluated against three cancer (MCF7, A2780 and HT29, IC<sub>50</sub> = 0.01-40.50 \u03bcM) and one normal MRC5 (IC<sub>50</sub> = 1.27-24.06 \u03bcM) cell lines using the MTT assay. The results revealed the highest antiproliferative activity against MCF7 cells for <b>16g</b> (IC<sub>50</sub> = 0.01 \u03bcM) with an exceptionally high selectivity index of (SI = 578). Cell cycle analysis of MCF7 cells treated with compound <b>16g</b> revealed a cell cycle arrest at the G<sub>2</sub>/M phase. In addition, compound <b>16g</b> induced a dose-dependent increase in apoptotic events in MCF7 cells compared to the control. In silico target prediction of compound <b>16g</b> showed six potential targets that could mediate these activities. Molecular docking analysis of compound <b>16g</b> revealed high binding affinities toward COX-2, MAP P38\u03b1, EGFR, and CDK2. The results of the MD simulation revealed low RMSD values and high negative binding free energies for the two complexes formed between compound <b>16g</b> with EGFR, and CDK2, while COX-2 was in the third order. These results highlighted a great potentiality for <b>16g</b> to inhibit both CDK2 and EGFR. Taken together, the results mentioned above highlighted compound <b>16g</b> as a potential anticancer agent."]}, "AuthorList": [{"Identifier": ["0000-0003-4048-1526"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Almalki", "ForeName": "Faisal A", "Initials": "FA"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": ["0000-0002-3035-661X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Central Laboratory for Micro-analysis, Minia University, Minia 61519, Egypt."}], "LastName": "Shawky", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, School of Pharmacy, Badr University in Cairo (BUC), Cairo 11829, Egypt."}], "LastName": "El Hassab", "ForeName": "Mahmoud A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt."}], "LastName": "Gouda", "ForeName": "Ahmed M", "Initials": "AM"}], "GrantList": [{"GrantID": "19-MED-1-01-0001", "Agency": "Deanship of Scientific Research at Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrroles"}, {"RegistryNumber": "0", "NameOfSubstance": "Schiff Bases"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle Checkpoints"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "HT29 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "MCF-7 Cells"}, {"QualifierName": [], "DescriptorName": "Models, Biological"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Pyrroles"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Schiff Bases"}, {"QualifierName": [], "DescriptorName": "Software"}], "CoiStatement": "The authors declared that there is no conflict of interest and have approved the article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7\u201333. doi: 10.3322/caac.21654.", "ArticleIdList": ["10.3322/caac.21654", "33433946"]}, {"Citation": "Gouda A.M., Beshr E.A., Almalki F.A., Halawah H.H., Taj B.F., Alnafaei A.F., Alharazi R.S., Kazi W.M., AlMatrafi M.M. Arylpropionic acid-derived NSAIDs: New insights on derivatization, anticancer activity and potential mechanism of action. Bioorg. Chem. 2019;92 doi: 10.1016/j.bioorg.2019.103224.", "ArticleIdList": ["10.1016/j.bioorg.2019.103224", "31491568"]}, {"Citation": "Rayburn E.R., Ezell S.J., Zhang R. Anti-Inflammatory Agents for Cancer Therapy. Mol. Cell. Pharmacol. 2009;1:29\u201343. doi: 10.4255/mcpharmacol.09.05.", "ArticleIdList": ["10.4255/mcpharmacol.09.05", "PMC2843097", "20333321"]}, {"Citation": "Li J., Hao Q., Cao W., Vadgama J.V., Wu Y. Celecoxib in breast cancer prevention and therapy. Cancer Manag. Res. 2018;10:4653\u20134667. doi: 10.2147/CMAR.S178567.", "ArticleIdList": ["10.2147/CMAR.S178567", "PMC6208493", "30464589"]}, {"Citation": "Kerr D.J., Chamberlain S., Kerr R.S. Celecoxib for Stage III Colon Cancer. JAMA. 2021;325:1257\u20131258. doi: 10.1001/jama.2021.2651.", "ArticleIdList": ["10.1001/jama.2021.2651", "33821916"]}, {"Citation": "Casanova I., Parre\u00f1o M., Farr\u00e9 L., Guerrero S., C\u00e9spedes M.V., Pavon M.A., Sancho F.J., Marcuello E., Trias M., Mangues R. Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. Int. J. Cancer. 2006;118:2381\u20132389. doi: 10.1002/ijc.21662.", "ArticleIdList": ["10.1002/ijc.21662", "16353145"]}, {"Citation": "Suri A., Sheng X., Schuler K.M., Zhong Y., Han X., Jones H.M., Gehrig P.A., Zhou C., Bae-Jump V.L. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016;7:39582\u201339594. doi: 10.18632/oncotarget.8659.", "ArticleIdList": ["10.18632/oncotarget.8659", "PMC5129955", "27074576"]}, {"Citation": "Wen B., Wei Y.-T., Mu L.-L., Wen G.-R., Zhao K. The molecular mechanisms of celecoxib in tumor development. Medicine. 2020;99:e22544. doi: 10.1097/MD.0000000000022544.", "ArticleIdList": ["10.1097/MD.0000000000022544", "PMC7535670", "33019464"]}, {"Citation": "Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 2002;277:27613\u201327621. doi: 10.1074/jbc.M201119200.", "ArticleIdList": ["10.1074/jbc.M201119200", "12000750"]}, {"Citation": "Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 2000;275:11397\u201311403. doi: 10.1074/jbc.275.15.11397.", "ArticleIdList": ["10.1074/jbc.275.15.11397", "10753955"]}, {"Citation": "Chun K.-S., Kim S.-H., Song Y.-S., Surh Y.-J. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis. 2004;25:713\u2013722. doi: 10.1093/carcin/bgh076.", "ArticleIdList": ["10.1093/carcin/bgh076", "14729583"]}, {"Citation": "Zhang Z., Chen F., Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag. Res. 2018;10:4631\u20134640. doi: 10.2147/CMAR.S175212.", "ArticleIdList": ["10.2147/CMAR.S175212", "PMC6197827", "30410398"]}, {"Citation": "Joishy S.K., Walsh D. The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: Application in bone metastases and the opioid bowel syndrome. J. Pain Symptom Manag. 1998;16:334\u2013339. doi: 10.1016/S0885-3924(98)00081-5.", "ArticleIdList": ["10.1016/S0885-3924(98)00081-5", "9846029"]}, {"Citation": "Nguyen B.C.Q., Takahashi H., Uto Y., Shahinozzaman M.D., Tawata S., Maruta H. 1,2,3-Triazolyl ester of Ketorolac: A \u201cClick Chemistry\u201d-based highly potent PAK1-blocking cancer-killer. Eur. J. Med. Chem. 2017;126:270\u2013276. doi: 10.1016/j.ejmech.2016.11.038.", "ArticleIdList": ["10.1016/j.ejmech.2016.11.038", "27889630"]}, {"Citation": "Gouda A.M., Abdelazeem A.H. An integrated overview on pyrrolizines as potential anti-inflammatory, analgesic and antipyretic agents. Eur. J. Med. Chem. 2016;114 doi: 10.1016/j.ejmech.2016.01.055.", "ArticleIdList": ["10.1016/j.ejmech.2016.01.055", "26994693"]}, {"Citation": "Becker J.C., Domschke W., Pohle T. Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond. Br. J. Clin. Pharmacol. 2004;58:587\u2013600. doi: 10.1111/j.1365-2125.2004.02198.x.", "ArticleIdList": ["10.1111/j.1365-2125.2004.02198.x", "PMC1884640", "15563357"]}, {"Citation": "Liu W., Zhou J., Bensdorf K., Zhang H., Liu H., Wang Y., Qian H., Zhang Y., Wellner A., Rubner G., et al. Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives. Eur. J. Med. Chem. 2011;46:907\u2013913. doi: 10.1016/j.ejmech.2011.01.002.", "ArticleIdList": ["10.1016/j.ejmech.2011.01.002", "21295381"]}, {"Citation": "Tavolari S., Bonaf\u00e8 M., Marini M., Ferreri C., Bartolini G., Brighenti E., Manara S., Tomasi V., Laufer S., Guarnieri T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis. 2008;29:371\u2013380. doi: 10.1093/carcin/bgm265.", "ArticleIdList": ["10.1093/carcin/bgm265", "18033773"]}, {"Citation": "Narayanan N.K., Nargi D., Attur M., Abramson S.B., Narayanan B.A. Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Res. 2007;27:2393\u20132402.", "ArticleIdList": ["17695530"]}, {"Citation": "Gouda A.M., Abdelazeem A.H., Abdalla A.N., Ahmed M. Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer activities. Acta Pharm. 2018;68 doi: 10.2478/acph-2018-0026.", "ArticleIdList": ["10.2478/acph-2018-0026", "31259695"]}, {"Citation": "Yu W., MacKerell A.D.J. Computer-Aided Drug Design Methods. Methods Mol. Biol. 2017;1520:85\u2013106. doi: 10.1007/978-1-4939-6634-9_5.", "ArticleIdList": ["10.1007/978-1-4939-6634-9_5", "PMC5248982", "27873247"]}, {"Citation": "Baig M.H., Ahmad K., Rabbani G., Danishuddin M., Choi I. Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders. Curr. Neuropharmacol. 2018;16:740\u2013748. doi: 10.2174/1570159X15666171016163510.", "ArticleIdList": ["10.2174/1570159X15666171016163510", "PMC6080097", "29046156"]}, {"Citation": "Agamah F.E., Mazandu G.K., Hassan R., Bope C.D., Thomford N.E., Ghansah A., Chimusa E.R. Computational/in silico methods in drug target and lead prediction. Brief. Bioinform. 2020;21:1663\u20131675. doi: 10.1093/bib/bbz103.", "ArticleIdList": ["10.1093/bib/bbz103", "PMC7673338", "31711157"]}, {"Citation": "Sunseri J., Koes D.R. Pharmit: Interactive exploration of chemical space. Nucleic Acids Res. 2016;44:W442\u2013W448. doi: 10.1093/nar/gkw287.", "ArticleIdList": ["10.1093/nar/gkw287", "PMC4987880", "27095195"]}, {"Citation": "Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644\u2013648. doi: 10.1038/384644a0.", "ArticleIdList": ["10.1038/384644a0", "8967954"]}, {"Citation": "Wang J.L., Limburg D., Graneto M.J., Springer J., Hamper J.R.B., Liao S., Pawlitz J.L., Kurumbail R.G., Maziasz T., Talley J.J., et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life. Bioorg. Med. Chem. Lett. 2010;20:7159\u20137163. doi: 10.1016/j.bmcl.2010.07.054.", "ArticleIdList": ["10.1016/j.bmcl.2010.07.054", "20709553"]}, {"Citation": "Orlando B.J., Malkowski M.G. Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta Crystallogr. Sect. F Struct. Biol. Commun. 2016;72:772\u2013776. doi: 10.1107/S2053230X16014230.", "ArticleIdList": ["10.1107/S2053230X16014230", "PMC5053162", "27710942"]}, {"Citation": "Dassault systems BIOVIA . Discovery Studio Visualizer, v16.1.0.15350. Dassault Systems; San Diego, CA, USA: 2016."}, {"Citation": "Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., et al. Rofecoxib [Vioxx, MK-0966; 4-(4\u2032-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 1999;290:551\u2013560.", "ArticleIdList": ["10411562"]}, {"Citation": "SwissADME.  [(accessed on 30 April 2021)]; Available online:  http://www.swissadme.ch/"}, {"Citation": "Molsoft.  [(accessed on 30 April 2021)]; Available online:  http://molsoft.com/mprop/"}, {"Citation": "Shawky A.M., Abdalla A.N., Ibrahim N.A., Abourehab M.A., Gouda A.M. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities. Eur. J. Med. Chem. 2021;218:113403. doi: 10.1016/j.ejmech.2021.113403.", "ArticleIdList": ["10.1016/j.ejmech.2021.113403", "33823396"]}, {"Citation": "Shawky A.M., Ibrahim N.A., Abourehab M.A.S., Abdalla A.N., Gouda A.M. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. J. Enzyme Inhib. Med. Chem. 2021;36 doi: 10.1080/14756366.2020.1837124.", "ArticleIdList": ["10.1080/14756366.2020.1837124", "PMC7594867", "33103497"]}, {"Citation": "Elsaady M.T., Gouda A.M., Edrees F.H., Gawad N.M.A. synthesis and biological evaluation of some novel Schiff base derivatives as potential anticancer agents. J. Chem. Pharm. Res. 2016;8:273\u2013282."}, {"Citation": "Alkahtani H.M., Alanazi M.M., Aleanizy F.S., Alqahtani F.Y., Alhoshani A., Alanazi F.E., Almehizia A.A., Abdalla A.N., Alanazi M.G., El-Azab A.S., et al. Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies. Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc. 2019;27:682\u2013693. doi: 10.1016/j.jsps.2019.04.003.", "ArticleIdList": ["10.1016/j.jsps.2019.04.003", "PMC6598223", "31297023"]}, {"Citation": "Abdalla A.N., Malki W.H., Qattan A., Shahid I., Hossain M.A., Ahmed M. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer. Molecules. 2021;26:334. doi: 10.3390/molecules26020334.", "ArticleIdList": ["10.3390/molecules26020334", "PMC7827067", "33440689"]}, {"Citation": "Abdalla A.N., Qattan A., Malki W.H., Shahid I., Hossain M.A., Ahmed M. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer. Molecules. 2020;25:4606. doi: 10.3390/molecules25204606.", "ArticleIdList": ["10.3390/molecules25204606", "PMC7594023", "33050377"]}, {"Citation": "Hixson L.J., Alberts D.S., Krutzsch M., Einsphar J., Brendel K., Gross P.H., Paranka N.S., Baier M., Emerson S., Pamukcu R. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Prev. Biomark. 1994;3:433\u2013438.", "ArticleIdList": ["7920212"]}, {"Citation": "Daina A., Michielin O., Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357\u2013W364. doi: 10.1093/nar/gkz382.", "ArticleIdList": ["10.1093/nar/gkz382", "PMC6602486", "31106366"]}, {"Citation": "Koul H.K., Pal M., Koul S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer. 2013;4:342\u2013359. doi: 10.1177/1947601913507951.", "ArticleIdList": ["10.1177/1947601913507951", "PMC3863344", "24349632"]}, {"Citation": "Simard J.R., Getlik M., Gr\u00fctter C., Pawar V., Wulfert S., Rabiller M., Rauh D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J. Am. Chem. Soc. 2009;131:13286\u201313296. doi: 10.1021/ja902010p.", "ArticleIdList": ["10.1021/ja902010p", "19572644"]}, {"Citation": "Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002;277:46265\u201346272. doi: 10.1074/jbc.M207135200.", "ArticleIdList": ["10.1074/jbc.M207135200", "12196540"]}, {"Citation": "Wyatt P.G., Woodhead A.J., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Davis D.J., Devine L.A., Early T.R., Feltell R.E., et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem. 2008;51:4986\u20134999. doi: 10.1021/jm800382h.", "ArticleIdList": ["10.1021/jm800382h", "18656911"]}, {"Citation": "Karoulia Z., Wu Y., Ahmed T.A., Xin Q., Bollard J., Krepler C., Wu X., Zhang C., Bollag G., Herlyn M., et al. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. 2016;30:485\u2013498. doi: 10.1016/j.ccell.2016.06.024.", "ArticleIdList": ["10.1016/j.ccell.2016.06.024", "PMC5021590", "27523909"]}, {"Citation": "Sun Q., Zhou J., Zhang Z., Guo M., Liang J., Zhou F., Long J., Zhang W., Yin F., Cai H., et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol. Ther. 2014;15:1635\u20131645. doi: 10.4161/15384047.2014.964087.", "ArticleIdList": ["10.4161/15384047.2014.964087", "PMC4622458", "25482937"]}, {"Citation": "Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785\u20132791. doi: 10.1002/jcc.21256.", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "Daina A., Michielin O., Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717.", "ArticleIdList": ["10.1038/srep42717", "PMC5335600", "28256516"]}, {"Citation": "Djoumbou-Feunang Y., Fiamoncini J., Gil-de-la-Fuente A., Greiner R., Manach C., Wishart D.S. BioTransformer: A comprehensive computational tool for small molecule metabolism prediction and metabolite identification. J. Cheminform. 2019;11:2. doi: 10.1186/s13321-018-0324-5.", "ArticleIdList": ["10.1186/s13321-018-0324-5", "PMC6689873", "30612223"]}, {"Citation": "Almalki F.A., Gouda A.M., Ali M.H.B., Almehmadi O.M. Profens: A comparative molecular docking study into cyclooxygenase-1/2. Drug Invent. Today. 2019;11:480\u2013487."}, {"Citation": "Mohamed F.A.M., Gomaa H.A., Hendawy O., Ali A.T., Farghaly H.S., Gouda A.M., Abdelazeem A.H., Abdelrahman M.H., Trembleau L., Youssif B.G.M. Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity. Bioorg. Chem. 2021;112:104960. doi: 10.1016/j.bioorg.2021.104960.", "ArticleIdList": ["10.1016/j.bioorg.2021.104960", "34020242"]}, {"Citation": "Abraham M.J., Murtola T., Schulz R., P\u00e1ll S., Smith J.C., Hess B., Lindahl E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1\u20132:19\u201325. doi: 10.1016/j.softx.2015.06.001.", "ArticleIdList": ["10.1016/j.softx.2015.06.001"]}, {"Citation": "Malde A.K., Zuo L., Breeze M., Stroet M., Poger D., Nair P.C., Oostenbrink C., Mark A.E. An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. J. Chem. Theory Comput. 2011;7:4026\u20134037. doi: 10.1021/ct200196m.", "ArticleIdList": ["10.1021/ct200196m", "26598349"]}, {"Citation": "Bhardwaj V.K., Singh R., Sharma J., Rajendran V., Purohit R., Kumar S. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J. Biomol. Struct. Dyn. 2020:1\u201310. doi: 10.1080/07391102.2020.1766572.", "ArticleIdList": ["10.1080/07391102.2020.1766572", "PMC7256349", "32397940"]}, {"Citation": "Chiu S.-W., Pandit S.A., Scott H.L., Jakobsson E. An Improved United Atom Force Field for Simulation of Mixed Lipid Bilayers. J. Phys. Chem. B. 2009;113:2748\u20132763. doi: 10.1021/jp807056c.", "ArticleIdList": ["10.1021/jp807056c", "19708111"]}, {"Citation": "Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., DiNola A., Haak J.R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984;81:3684\u20133690. doi: 10.1063/1.448118.", "ArticleIdList": ["10.1063/1.448118"]}, {"Citation": "Parrinello M., Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 1981;52:7182\u20137190. doi: 10.1063/1.328693.", "ArticleIdList": ["10.1063/1.328693"]}, {"Citation": "Kumari R., Kumar R., Lynn A. g_mmpbsa\u2014A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model. 2014;54:1951\u20131962. doi: 10.1021/ci500020m.", "ArticleIdList": ["10.1021/ci500020m", "24850022"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "10"}, {"Year": "2021", "Month": "6", "Day": "25"}, {"Year": "2021", "Month": "6", "Day": "27"}, {"Year": "2021", "Month": "7", "Day": "2", "Hour": "1", "Minute": "36"}, {"Year": "2021", "Month": "7", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "30"}], "PublicationStatus": "epublish", "ArticleIdList": ["34209011", "PMC8271847", "10.3390/molecules26134002", "molecules26134002"]}}], "PubmedBookArticle": []}